Showing results (191-200 of 251) with videos related to
Sort By:
Pageof 26
Journal of Crohn'S & Colitis|May 18, 2025
Distinct perturbances in metabolic pathways associate with disease progression in inflammatory bowel diseaseArno R Bourgonje, Susanne Ibing, Alexandra E Livanos, et al.The American Journal of Gastroenterology|May 7, 2019
Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's DiseaseJing Wu, David M Lubman, Subra Kugathasan, et al.Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.Inflammatory Bowel Diseases|August 22, 2020
Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United StatesBenjamin L Cohen, Zane R Gallinger, Christina Ha, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction TreatmentRemo Panaccione, Marc Ferrante, Iris Dotan, et al.Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.Lancet (London, England)|March 5, 2023
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesWilliam J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, et al.Inflammatory Bowel Diseases|December 6, 2021
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVIDKimberly N Weaver, Xian Zhang, Xiangfeng Dai, et al.Gastroenterology|February 15, 2017
Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel DiseaseJeffrey S Hyams, Marla C Dubinsky, Robert N Baldassano, et al.Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.Pageof 26